Genetic risk of prostate cancer
Authors:
Milan Král 1; Vlasta Vyhnánková 1; Vladimír Študent 1; Jan Bouchal 2
Authors place of work:
Urologická klinika LF UP a FN, Olomouc
1; Laboratoř molekulární patologie LF UP, Olomouc
2
Published in the journal:
Ces Urol 2010; 14(3): 139-147
Category:
Review article
Summary
Prostate cancer is a disease which origin is affected appart from enviromental factors also by genetic factors. Despite extensive research, the ethiopathogenesis of prostate cancer is only slightly explored. According to genetic risk we distinguish between sporadic cancers (mostly prevalent), familial and hereditary cancers. From genetic abnormalities mostly seen in prostate cancer we can name genetic changes in gene for androgen receptor, from other candidate genes there is RNAseL on locus HPC1, genes ELAC2, MSR1, BRCA 1 a 2, fusion genes TMPRSS2+ERG/ETV, KLF6 etc. With the development of molecular biologic methods we have more options to understand causations of prostate cancer origin and we can better influence further course of the disease. The aim of this overview is to present current status of genetic risk for prostate cancer development.
Key words:
genetics, prostate cancer, risk.
Zdroje
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.
2. Merrill RM, Stephenson RA. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening. J Urol 2000; 163: 503–510.
3. Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228–1242.
4. http://www.svod.cz
5. Strope SA, Andriole GL. Update on chemoprevention for prostate cancer. Curr Opin Urol 2010; 20: 194–197.
6. Dvořáček J. Nádory prostaty. In: Dvořáček J, Babjuk M, et al. Onkourologie, 1. vydání. Praha: Galén 2005; 225–242.
7. Klein EA, Platz EA, Thompson IM. Epidemiology, Etiology, and Prevention of Prostate Cancer. In: Wein AJ, Kavoussi LR, et al. Campbell-Walsh Urology, 9th ed. Philadelphia: Saunders 2007; 2854–2867
8. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367–3371.
9. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002; 168: 906–913.
10. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797–802.
11. Schaid DJ, McDonnell SK, Blute ML, Thibodeau SN. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998; 62: 1425–1438.
12. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003; 97: 1894–1903.
13. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer 2003; 107: 797–803.
14. Kalish LA, McDougal WS, McKinlay JB. Family history and the risk of prostate cancer. Urology 2000; 56: 803–806.
15. Mastalski K, Coups EJ, Ruth K, Raysor S, Giri VN. Substantial family history of prostate cancer in black men recruited for prostate cancer screening: results from the Prostate Cancer Risk Assessment Program. Cancer 2008; 113: 2559–2564.
16. Chen YC, Page JH, Chen R, Giovannucci E. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate 2008; 68: 1582–1591.
17. Valeri A, Briollais L, Azzouzi R, et al. Segregation analysis of prostate cancer in France: evidence for autosomal dominant inheritance and residual brother-brother dependence. Ann Hum Genet 2003; 67: 125–137.
18. Verhage BA, Baffoe-Bonnie AB, Baglietto L, et al. Autosomal dominant inheritance of prostate cancer: a confirmatory study. Urology 2001; 57: 97–101.
19. Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: a study of World War II veteran twins. Prostate 1997; 33: 240–245.
20. Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994; 152: 1484–1487; discussion 1487–1489.
21. Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA. Family history of prostate cancer in patients with localized prostate cancer: an independent predictor of treatment outcome. J Clin Oncol 1997; 15: 1478–1480.
22. Bova GS, Partin AW, Isaacs SD, et al. Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol 1998; 160: 660–663.
23. Gronberg H, Damber L, Tavelin B, Damber JE. No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 1998; 82: 564–567.
24. Hanlon AL, Hanks GE. Patterns of inheritance and outcome in patients treated with external beam radiation for prostate cancer. Urology 1998; 52: 735–738.
25. Herkommer K, Paiss T, Merz M, Gschwend JE, Kron M. Association of a positive family history with histopathology and clinical course in early-onset prostate cancer. Urologe A 2006; 45: 1532–1539.
26. Roupret M, Fromont G, Bitker MO, Gattegno B, Vallancien G, Cussenot O. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Urology 2006; 67: 1028–1032.
27. Robbins AS, Yin D, Parikh-Patel A. Differences in prognostic factors and survival among White men and Black men with prostate cancer, California, 1995–2004. Am J Epidemiol 2007; 166: 71–78.
28. Gottlieb B, Beitel LK, Wu JH, Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat 2004; 23: 527–533.
29. Brooke GN, Bevan CL. The role of androgen receptor mutations in prostate cancer progression. Curr Genomics 2009; 10: 18–25.
30. Lukeš M. Hereditární karcinom prostaty. In: Záleský M, Lukeš M. Molekulární genetika karcinomu prostaty. Praha: Galén 2002; 77–89.
31. Narla G, Friedman SL, Martignetti JA. Kruppel cripples prostate cancer: KLF6 progress and prospects. Am J Pathol 2003; 162: 1047–1052.
32. Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 2003; 10: 209–216.
33. Chen C, Lamharzi N, Weiss NS, et al. Androgen receptor polymorphisms and the incidence of prostate cancer. Cancer Epidemiol Biomarkers Prev 2002; 11: 1033–1040.
34. Silva Neto B, Koff WJ, Biolchi V, et al. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: analysis of a Brazilian population. Cancer Invest 2008; 26: 74–80.
35. Brinkmann AO. Molecular basis of androgen insensitivity. Mol Cell Endocrinol 2001; 179: 105–109.
36. Marcelli M, Ittmann M, Mariani S, et al. Androgen receptor mutations in prostate cancer. Cancer Res 2000; 60: 944–949.
37. Ntais C, Polycarpou A, Ioannidis JP. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta–analysis. Cancer Epidemiol Biomarkers Prev 2003; 12: 618–624.
38. Cunningham JM, Hebbring SJ, McDonnell SK, et al. Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 969–978.
39. Ostrander EA, Johannesson B. Prostate cancer susceptibility loci: finding the genes. Adv Exp Med Biol 2008; 617: 179–190.
40. Stanford JL, McDonnell SK, Friedrichsen DM, et al. Prostate cancer and genetic susceptibility: a genome scan incorporating disease aggressiveness. Prostate 2006; 66: 317–325.
41. Easton DF, Schaid DJ, Whittemore AS, Isaacs WJ. Where are the prostate cancer genes?
A summary of eight genome wide searches. Prostate 2003; 57: 261–269.
42. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;
13(Spec No 1): R103–R121.
43. Hatcher D, Daniels G, Osman I, Lee P. Molecular mechanisms involving prostate cancer
racial disparity. Am J Transl Res 2009; 1: 235–248.
44. Simard J, Dumont M, Labuda D, et al. Prostate cancer susceptibility genes: lessons learned
and challenges posed. Endocr Relat Cancer 2003; 10: 225–259.
45. http://www.ncbi.nlm.nih.gov/entrez/ (OMIM – Online Mendelian Inheritance in Men)
46. Klein EA. Genetická náchylnost a oxidační stres u karcinomu prostaty: integrovaný model s doporučeními pro prevenci. Urol List 2006; 4(4): 19–24.
47. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371–1374.
48. Gronberg H, Isaacs SD, Smith JR, et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA 1997; 278: 1251–1255.
49. Li H, Tai BC. RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin Cancer Res 2006; 12: 5713–5719.
50. Shook SJ, Beuten J, Torkko KC, et al. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res 2007; 13: 5959–5964.
51. Rennert H, Bercovich D, Hubert A, et al. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002; 71: 981–984.
52. Orr-Urtreger A, Bar-Shira A, Bercovich D, et al. RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2006; 15: 474–479.
53. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci USA 2009; 106: 16351–16356.
54. Rebbeck TR, Walker AH, Zeigler-Johnson C, et al. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet 2000; 67: 1014–1019.
55. Shea PR, Ferrell RE, Patrick AL, Kuller LH, Bunker CH. ELAC2 and prostate cancer risk in Afro-Caribbeans of Tobago. Hum Genet 2002; 111: 398–400.
56. Kouprina N, Pavlicek A, Noskov VN, et al. Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27. Genome Res 2005; 15: 1477–1486.
57. Baffoe-Bonnie AB, Smith JR, Stephan DA, et al. A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. Hum Genet 2005; 117: 307–316.
58. Farnham JM, Camp NJ, Swensen J, Tavtigian SV, Albright LA. Confirmation of the HPCX prostate cancer predisposition locus in large Utah prostate cancer pedigrees. Hum Genet 2005; 116: 179–185.
59. Sun J, Hsu FC, Turner AR, et al. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. Prostate 2006; 66: 728–737.
60. Berry R, Schroeder JJ, French AJ, et al. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 2000; 67: 82–91.
61. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644–648.
62. Jamaspishvili T, Kral M, Khomeriki I, Student V, Kolar Z, Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 12–19.
63. Albadine R, Latour M, Toubaji A, et al. TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. Mod Pathol 2009; 22: 1415–1422.
64. Koivisto PA, Hyytinen ER, Matikainen M, Tammela TL, Ikonen T, Schleutker J. Kruppellike factor 6 germ-line mutations are infrequent in Finnish hereditary prostate cancer. J Urol 2004; 172: 506–507.
65. Dong JT. Prevalent mutations in prostate cancer. J Cell Biochem 2006; 97: 433–447.
Štítky
Paediatric urologist Nephrology UrologyČlánok vyšiel v časopise
Czech Urology
2010 Číslo 3
Najčítanejšie v tomto čísle
- Microsurgical varicocelectomy in children and adolescents: prospective comparison of laparoscopic and open subinguinal repair
- Our experience with shock waves therapy in patiens with Peyronie’s disease (average follow-up of 13 months)
- Position of magnetic resonance and magnetic resonance with spectroscopy in detection of prostate cancer
- Molecular characteristics of clinically significant prostate carcinoma